About this event
Join us on August 30th as we chat with Barbara Vodicska, Ph.D., Dr. Sean Khozin, Robert Doczi, Ph.D., and Dr. Istvan Petak, of Genomate, about the future outlook for AI in precision oncology.
Genomate helps oncologists determine the optimal targeted therapy for every cancer patient based on the individual molecular profile of their tumor. It's the world's first AI-powered clinical decision support system for precision oncology, transforming the lives of countless cancer patients. It is being developed by Genomate Health Inc, a team of experienced oncology, AI, and business professionals dedicated to revolutionizing cancer treatment and care for every patient.
Expert in precision oncology and molecular pharmacology of targeted therapies with 25+ years of experience. He is the founder and CEO of Genomate Health, Inc., founder and board director of Oncompass Medicine, Budapest, HU, and adjunct professor at the Department of Pharmaceutical Sciences at the University of Illinois at Chicago (UIC).
Barbara Vodicska is a trained biochemical engineer with expertise in studying the molecular background of prion diseases and cancer. She completed her doctoral research at the German Cancer Research Center (DKFZ) in Heidelberg. Currently, she holds the position of Head of Translational Science at Genomate Health, where she contributes to research and development efforts focused on a software as a medical device. This revolutionary software aims to improve targeted therapy decisions in the field of precision oncology.
Robert Doczi PhD is a molecular biologist with over 20 years’ experience in cellular signaling. He is currently Head of Research at Genomate Health, where he is involved in the development and clinical validation of a novel computational method that implements cognitive computing in precision oncology. Previously he was a postdoctoral researcher at Vienna Biocenter (Austria) and was a Marie Curie Fellow at Royal Holloway, University of London (UK) and, before joining the company, he was a principal investigator at the Hungarian Academy of Sciences.
Chris holds a PhD in Medicine and is interested in the use of computation to solve biomedical problems. Currently, Chris heads DrugBank’s Scientific Support team, where he is responsible for staying on top of the latest trends and biomedical research.
Dr. Sean Khozin is a globally recognized oncologist, data scientist, and physician-executive with extensive experience in therapeutic development and AI applications in biomedical research. As the founder of Phyusion and Senior Partner at Braven, he focuses on advancing innovations at the nexus of biology, technology, and AI. Previously, he was the CEO of CancerLinQ, the Global Head of Data Strategy at Johnson & Johnson, and a founding member of the US FDA’s Oncology Center of Excellence in addition to serving as the founding executive director of INFORMED, FDA’s first science and technology incubator. Dr. Khozin is the cofounder of the technology company Hello Health and founder of SKMD, a multidisciplinary network of clinics utilizing telemedicine and remote monitoring tools to improve patient outcomes. He is a Research Affiliate at MIT and started his clinical research work at the US National Cancer Institute developing molecular profiling strategies in thoracic malignancies.
A global provider of drug data solutions that accelerate drug research and improve healthcare delivery.
Share this event